RecruitingPhase 2NCT07224438

Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea


Sponsor

Stephanie B. Seminara, MD

Enrollment

20 participants

Start Date

Dec 9, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in women with hypothalamic amenorrhea (HA). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Kisspeptin will be administered subcutaneously (SC) for two weeks in a pulsatile fashion. Ultrasound monitoring of ovarian follicular growth and frequent blood sampling (every 10 minutes for up to two hours) will be performed to assess the physiologic response to kisspeptin over time.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 45 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called kisspeptin 112-121 for people with hypogonadotropic hypogonadism and hypothalamic amenorrhea. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years to 45 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGkisspeptin 112-121

SC administration of kisspeptin for two weeks (pulsatile, approximately every 90 minutes)


Locations(1)

Massachusetts General Hospital

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07224438


Related Trials